AR and prostate carcinoma: Whereas previous studies delineate expression of AR-V3 as a potential biomarker in the context of ARTA resistance, our results question the genuine role of AR-V3 as a tumor-promoting resistance mechanism in prostate cancer and thus, its value as a clinical biomarker.